Ciphergen to Use Proteomics Technology to Develop Cancer Diagnostics with Johns Hopkins | GenomeWeb

NEW YORK, Nov 29 – ProteinChip-maker Ciphergen Biosystems said Wednesday that it would collaborate with Johns Hopkins University School of Medicine to develop proteomic diagnostic tests for cancer.

Ciphergen will use its ProteinChip System to discover and validate protein biomarkers in cancer serum samples provided by Johns Hopkins. The university will also provide the clinical expertise of its physicians and scientists.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.